Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.
Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those <80 years of age (OR 0.37; 95% CI 0.15-0.93) but not for those aged >or=80 years (OR 0.56; 95% CI 0.15-2.10). The reduced risk was significant for statins but not for other LLAs. Adjusting for apolipoprotein E4 status did not change the point estimates of the ORs. The greatest impact of LLAs was seen in the CIND subtype circumscribed memory impairment.
Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada. kenneth.rockwood@dal.ca
Kenneth
K
Rockwood
Susan
S
Howlett
John
J
Fisk
Sultan
S
Darvesh
Holly
H
Tuokko
David B
DB
Hogan
Christina
C
Wolfson
Ian
I
McDowell
D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000544:Alzheimer Disease / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D001057:Apolipoproteins E / Q000235:genetics*; D002170:Canada; D016022:Case-Control Studies; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005838:Genotype; D015577:Geriatric Assessment; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D008569:Memory Disorders / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D008609:Mental Status Schedule; D016017:Odds Ratio; D012307:Risk Factors
D001057:Apolipoproteins E; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents